Severe Asthma Digital Marketing Trends Report 2022: Assess Key Digital Marketing Metrics Including Branded Websites for Patients and Healthcare Professionals, Mobile Apps, and Social Media Accounts – ResearchAndMarkets.com – Business Wire

Lead Marketing & Automation Services > Blog > Uncategorized > Severe Asthma Digital Marketing Trends Report 2022: Assess Key Digital Marketing Metrics Including Branded Websites for Patients and Healthcare Professionals, Mobile Apps, and Social Media Accounts – ResearchAndMarkets.com – Business Wire

DUBLIN–()–The “Digital Marketing Trends in Severe Asthma” report has been added to ResearchAndMarkets.com’s offering.
Sanofi/Regeneron’s Dupixent.com achieved the highest traffic across branded severe asthma patient sites in the US from July 2021 to June 2022, with about 7,800,000 visits, followed by Novartis’ Xolair.com, and GSK’s Nucala.com.
The highest proportion of traffic to these sites originated from direct sources, followed by organic searches. Amgen/AstraZeneca’s Tezspire.com had the highest amount of direct traffic (83%), while remaining brands, Dupixent, Cinqair, Nucala, and Xolair, had levels between 52-66%.
For patient branded sites, Sanofi/Regeneron spent the most on DDA for Dupixent.com at approximately $4.2 million, followed by GSK’s Nucala.com at approximately $900,000. Dupixent.com was supported by the most paid keywords at approximately 10,650 keywords, followed by Tezspire.com at about 5,800 keywords.
For branded HCP sites in the US, Sanofi/Regeneron’s Dupixenthcp.com had the highest number of visits at approximately 775,000 total visits, followed by AstraZeneca’s Fasenrahcp.com, and GSK’s Nucalahcp.com. The highest proportion of traffic to these sites originated from direct, followed by organic and referral sources.
Teva’s Cinqairhcp.com had the highest proportion of traffic from direct searches (81%). Sanofi/Regeneron spent the most on DDA for Dupixenthcp.com at approximately $51,400, followed by Amgen/AstraZeneca’s Tezspirehcp.com at approximately $17,100.
Between July 2021 and June 2022, the top 20 social media asthma posts by interaction from pharma were from Sanofi’s Facebook accounts, Genentech’s Instagram, Regeneron’s Instagram, Fasenra’s Facebook, and GSK’s Instagram. AstraZeneca’s Vik Asthma is the only severe asthma app detected from pharma in the US, with an estimated 30,700 downloads in 2021.
Most branded websites in EUCAN are patient-directed and few generated notable traffic between July 2021 and June 2022. Sanofi/Regeneron’s Dupixentmyway.co.uk and Dupixent.co.uk achieved the highest traffic, with about 20,200 and 3,400 visits, respectively.
Between July 2021 and June 2022, eight of the top 20 social media asthma posts by interaction in EUCAN from pharma were from AstraZeneca Espana’s Instagram account. No asthma mobile apps were detected from pharma in EUCAN.
Scope
Reasons to Buy
 
Key Topics Covered:
Companies Mentioned
For more information about this report visit https://www.researchandmarkets.com/r/ce0gao
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

source